| 1 |
28377232 | Comparison of Safety and Efficacy of Unfractionated Heparin Versus Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. | 2017 Dec |
1 |
| 2 |
27583038 | Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention. | 2016 |
1 |
| 3 |
26102015 | Heparin Versus Bivalirudin in Contemporary Percutaneous Coronary Intervention: A Welcome Back to an Old Friend Unfractionated Heparin. | 2015 Jun |
1 |
| 4 |
26266343 | Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis. | 2015 Aug |
1 |
| 5 |
25389143 | Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. | 2014 Nov 11 |
1 |
| 6 |
24273488 | Promoting Effects of Heparin on ex vivo Expansion of Megakaryocytopoiesis from Human Cord Blood CD34+ Cells. | 2013 Oct |
2 |
| 7 |
22294539 | Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis. | 2012 Feb |
1 |
| 8 |
21060749 | Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor. | 2010 Nov |
2 |
| 9 |
24323522 | A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice. | 2010 Sep |
1 |
| 10 |
18484795 | Glycoprotein IIb/IIIa antagonists in acute ischaemic stroke: current status and future directions. | 2008 |
1 |
| 11 |
18579401 | Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade. | 2008 Sep |
1 |
| 12 |
17039513 | Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. | 2007 Apr |
3 |
| 13 |
17476038 | The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy. | 2007 May |
1 |
| 14 |
17540196 | Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). | 2007 Jun |
1 |
| 15 |
16637790 | Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention. | 2006 May |
2 |
| 16 |
16683212 | Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. | 2006 Jun |
1 |
| 17 |
16765113 | Planned versus provisional use of glycoprotein IIb/IIIa inhibitors in smokers undergoing percutaneous coronary intervention. | 2006 Jun 15 |
1 |
| 18 |
17102832 | Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. | 2006 Nov |
1 |
| 19 |
16079449 | A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. | 2005 Aug |
1 |
| 20 |
15085057 | Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: Part 2: When and how to use various agents. | 2004 Apr |
1 |
| 21 |
15201252 | Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention. | 2004 Jul |
1 |
| 22 |
15457395 | [Guideline-conforming interventional treatment of acute ST-segment elevation myocardial infarction in rural areas using network collaboration]. | 2004 Oct 8 |
1 |
| 23 |
15624282 | Revascularization strategies in acute myocardial infarction: a meta-analysis. | 2004 Dec |
1 |
| 24 |
12626998 | Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. | 2003 Mar |
2 |
| 25 |
12678189 | Use of abciximab and tirofiban in patients with peripheral arterial occlusive disease and arterial thrombosis. | 2003 Mar-Apr |
1 |
| 26 |
12749745 | Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. | 2003 |
2 |
| 27 |
12877649 | Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention? | 2003 Aug |
1 |
| 28 |
12919181 | Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans. | 2003 Sep |
2 |
| 29 |
12943500 | Low molecular weight heparins combined with platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. | 2003 Sep |
1 |
| 30 |
14529393 | Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. | 2003 |
1 |
| 31 |
14728074 | Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization. | 2003 |
2 |
| 32 |
11286313 | Glycoprotein IIb/IIIa inhibitors and low-molecular-weight heparins: a combined role in coronary interventions? | 2001 Mar |
1 |
| 33 |
11560299 | Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab. | 2001 Sep |
1 |
| 34 |
11560562 | Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects. | 2001 Sep |
4 |
| 35 |
11565896 | Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass. | 2001 Sep |
1 |
| 36 |
10731377 | [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. | 2000 Feb |
1 |
| 37 |
10735780 | The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. | 2000 Apr |
2 |
| 38 |
10793178 | The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. | 2000 Apr 27 |
1 |
| 39 |
10974231 | Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels. | 2000 Sep |
1 |
| 40 |
11019977 | GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. | 2000 Sep |
1 |
| 41 |
10468150 | Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. | 1999 Sep |
1 |
| 42 |
10502232 | Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors. | 1999 Oct |
1 |
| 43 |
10502235 | Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy. | 1999 Oct |
1 |
| 44 |
10532207 | Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon. | 1999 Aug |
1 |
| 45 |
10695486 | Unstable angina in 1998. | 1999 Sep |
1 |
| 46 |
12623570 | The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention. | 1999 |
1 |
| 47 |
9716161 | Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. | 1998 Aug |
2 |
| 48 |
9809888 | Heparin dosing in patients undergoing coronary intervention. | 1998 Oct 22 |
1 |
| 49 |
9013915 | The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies. | 1997 Jan |
1 |
| 50 |
9167024 | In vitro inhibition of heparin-induced platelet aggregation in plasma from patients with HIT by SR 121566, a newly developed Gp IIb/IIIa antagonist. | 1997 Apr |
1 |